Featured News

Team Gluten-Free runners from across the country will unite in New York to run the 26.2 miles with one common goal: to accelerate diagnosis, treatments, & a cure for the three million Americans affected by celiac disease.

A new Alcohol and Tobacco Tax and Trade Bureau (TTB) ruling released October 13 allows a gluten-free label on spirits distilled from gluten-containing grains.

One of our most important research investments over the last several years has been in iCureCeliac®, the nation’s celiac disease patient registry. This month, researchers published three important studies that used iCureCeliac® as the data source.

Researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation presented a study which concluded that despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives.

A study led by Columbia University and Celiac Disease Foundation researchers examined probiotic use among celiac disease patients and was an Outstanding Poster Presenter recipient at the 2020 ACG Annual Scientific Meeting.

The following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.

New research from Columbia University revealed differences in the antibodies present, adding evidence that NCGS involves a different kind of inflammation in the gut in response to gluten.

The first study of its kind in North America has found an increased risk for birth defects in children of women with active, untreated celiac disease.

The Celiac Disease Foundation is proud to partner with Mediaplanet for their Morning Nutrition campaign.

The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).